⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12836545 | 1.00 | — | — | |
| SCHEMBL16782434 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL28241275 | 0.97 | — | — | |
| Trifluoroacetic Acid SCHEMBL15414556 | 0.85 | PADI4 (0.34) | — | |
| SCHEMBL13594559 | 0.83 | ECE1 (0.36) | — | |
| SCHEMBL10207366 | 0.81 | — | — | |
| SCHEMBL8171872 | 0.81 | — | — | |
| SCHEMBL27534582 | 0.81 | CA1 (0.39) | — | |
| SCHEMBL3386310 | 0.81 | — | — | |
| SCHEMBL3867719 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116964048-A | Bicyclic tetrahydroazepine derivatives for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2023-10-27 | — | — | CN | claimed |
| EP-3057948-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2016-08-24 | — | — | EP | claimed |
| EP-2872490-A1 | ANTIPROLIFERATIVE BENZO [B]AZEPIN- 2 - ONES | F. Hoffmann-La Roche AG (CH) | 2015-05-20 | — | — | EP | claimed |
| WO-2015057655-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-23 | — | — | WO | claimed |
| WO-2014009495-A1 | ANTIPROLIFERATIVE BENZO [B] AZEPIN- 2 - ONES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-01-16 | — | — | WO | claimed |
| EP-2464368-A1 | CATHEPSIN C INHIBITORS | Glaxo Group Limited (GB) | 2012-06-20 | — | — | EP | claimed |
| EP-1902065-A2 | CYCLIC AMIDE DERIVATIVES INHIBITORS OF THE INHIBITOR OF APOPTOSIS PROTEINS, THEIR PREPARATION, AND THEIR USE | Novartis AG (CH) | 2008-03-26 | — | — | EP | claimed |
| WO-2006133147-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-12-14 | — | — | WO | claimed |
| EP-1412328-A1 | DOLASTATIN 10 DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2004-04-28 | — | — | EP | claimed |
| WO-2003008378-A1 | DOLASTATIN 10 DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2003-01-30 | — | — | WO | claimed |
| WO-2025235719-A1 | DIMERIC SMAC MIMETICS USEFUL IN HIV THERAPY | VIIV HEALTHCARE COMPANY (US) | 2025-11-13 | — | — | WO | disclosed |
| CN-113412271-B | Having cysteine residues Hamiltelin derivatives of (C) | 住友制药株式会社 | 2024-10-22 | — | — | CN | disclosed |
| CN-111032676-B | Antibody drug complexes comprising hamiltin derivatives | 住友制药株式会社 | 2024-08-23 | — | — | CN | disclosed |
| EP-3387445-B1 | ISOBARIC MASS LABELS | ELECTROPHORETICS LTD (GB) | 2023-02-08 | — | — | EP | disclosed |
| WO-2022266068-A2 | GLP-1 RECEPTOR AGONISTS HAVING IMPROVED PHARMACOLOGICAL AND DRUG DELIVERY PROPERTIES | RESOLUTE BIO, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| EP-0264091-B1 | 3-PROPENYLCEPHEM DERIVATIVE, PREPARATION THEREOF, CHEMICAL INTERMEDIATES THEREIN, PHARMACEUTICAL COMPOSITION AND USE | Eisai Co., Ltd. (JP) | 1992-02-05 | — | — | EP | disclosed |
| US-5066812-A | Chemical intermediates for bactericides | EISAI CO., LTD. (JP) | 1991-11-19 | — | — | US | disclosed |
| US-5006649-A | Bactericides | EISAI, CO. (JP) | 1991-04-09 | — | — | US | disclosed |
| US-4921850-A | GRAMNEGATIVE AND GRAMPOSITIVE BACTERICIDE | EISAI CO., LTD. (JP) | 1990-05-01 | — | — | US | disclosed |
| EP-0333154-A2 | Process for the preparation of cephem derivatives and intermediates therefor | Eisai Co., Ltd. (JP) | 1989-09-20 | — | — | EP | disclosed |